Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094)

Vaccine

Volumn 23, Issue 34, 2005, Pages 4292-4301

  Tubiana, Roland ^a   Carcelain, Guislaine ^b   Vray, Muriel ^a   Gourlain, Karine ^a   Dalban, Cécile ^a   Chermak, Aziza ^a   Rabian, Claire ^c   Vittecoq, Daniel ^d   Simon, Anne ^a   Bouvet, Elisabeth ^e   El Habib, Raphaelle ^f   Costagliola, Dominique ^a   Calvez, Vincent ^a   Autran, Brigitte ^b   Katlama, Christine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Laboratoire d'Immunologie Cellulaire et Tissulaire CNRS URA 625   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e BICHAT HOSPITAL   (France)

^f SANOFI PASTEUR   (France)

Author keywords

Clinical trial; HIV recombinant canarypox vaccine vCP1433; Therapeutic immunization

Indexed keywords

CD8 ANTIGEN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RECOMBINANT CANARYPOX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; INJECTION; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PAIN; PATIENT; PRIORITY JOURNAL; PROBABILITY; SYSTEMIC DISEASE; T LYMPHOCYTE; TREATMENT WITHDRAWAL;

ADULT; AIDS VACCINES; CANARYPOX VIRUS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VACCINES, SYNTHETIC;

EID: 22244471038     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.04.013     Document Type: Article

References (46)

1. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 13 1998 853 860
2. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, and M. Baseler Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci USA 94 24 1997 13193 13197
3. D. Finzi, J. Blankson, J.D. Siliciano, J.B. Margolick, K. Chadwick, and T. Pierson Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat Med 5 5 1999 512 517
4. N. Friis-Moller, C.A. Sabin, R. Weber, A. d'Arminio Monforte, W.M. El-Sadr, and P. Reiss Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med 349 21 2003 1993 2003
5. A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, and D.J. Chisholm A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 7 1998 F51 F58
6. E.S. Rosenberg, J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P.E. Sax, and S.A. Kalams Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia Science 278 5342 1997 1447 1450
7. R.A. Koup, J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, and W. Borkowsky Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome J Virol 68 7 1994 4650 4655
8. P. Borrow, H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B. Oldstone Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J Virol 68 9 1994 6103 6110
9. M.R. Klein, C.A. van Baalen, A.M. Holwerda, S.R. Kerkhof Garde, R.J. Bende, and I.P. Keet Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics J Exp Med 181 4 1995 1365 1372
10. C. Rinaldo, X.L. Huang, Z.F. Fan, M. Ding, L. Beltz, and A. Logar High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors J Virol 69 9 1995 5838 5842
11. J.E. Schmitz, M.J. Kuroda, S. Santra, V.G. Sasseville, M.A. Simon, and M.A. Lifton Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes Science 283 5403 1999 857 860
12. B. Autran, G. Carcelain, T.S. Li, C. Blanc, D. Mathez, and R. Tubiana Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease Science 277 5322 1997 112 116
13. M.M. Lederman, E. Connick, A. Landay, D.R. Kuritzkes, J. Spritzler, and M. St. Clair Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315 J Infect Dis 178 1 1998 70 79
14. C.J. Pitcher, C. Quittner, D.M. Peterson, M. Connors, R.A. Koup, and V.C. Maino HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression Nat Med 5 5 1999 518 525
15. G.S. Ogg, X. Jin, S. Bonhoeffer, P. Moss, M.A. Nowak, and S. Monard Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy J Virol 73 1 1999 797 800
16. C.M. Gray, J. Lawrence, J.M. Schapiro, J.D. Altman, M.A. Winters, and M. Crompton Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART) J Immunol 162 3 1999 1780 1788
17. L. Mollet, T.S. Li, A. Samri, C. Tournay, R. Tubiana, and V. Calvez Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study groups J Immunol 165 3 2000 1692 1704
18. X. Jin, G. Ogg, S. Bonhoeffer, J. Safrit, M. Vesanen, and D. Bauer An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes Mol Med 6 9 2000 803 809
19. G.M. Ortiz, D.F. Nixon, A. Trkola, J. Binley, X. Jin, and S. Bonhoeffer HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy J Clin Invest 104 6 1999 R13 R18
20. R.T. Davey Jr., N. Bhat, C. Yoder, T.W. Chun, J.A. Metcalf, and R. Dewar HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc Natl Acad Sci USA 96 26 1999 15109 15114
21. G. Carcelain, R. Tubiana, A. Samri, V. Calvez, C. Delaugerre, and H. Agut Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection J Virol 75 1 2001 234 241
22. L. Ruiz, G. Carcelain, J. Martinez-Picado, S. Frost, S. Marfil, and R. Paredes HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection AIDS 15 9 2001 F19 F27
23. A. Oxenius, D.A. Price, H.F. Gunthard, S.J. Dawson, C. Fagard, and L. Perrin Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection Proc Natl Acad Sci USA 99 21 2002 13747 13752
24. A.U. Neumann, R. Tubiana, V. Calvez, C. Robert, T.S. Li, and H. Agut HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group AIDS 13 6 1999 677 683
25. F. Garcia, M. Plana, G.M. Ortiz, S. Bonhoeffer, A. Soriano, and C. Vidal The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection AIDS 15 9 2001 29 40
26. D.C. Douek, J.M. Brenchley, M.R. Betts, D.R. Ambrozak, B.J. Hill, and Y. Okamoto HIV preferentially infects HIV-specific CD4+ T cells Nature 417 6884 2 May 2002 95 98
27. B. Autran, D. Costagliola, R. Murphy, and C. Katlama Evaluating therapeutic vaccines in patients infected with HIV Expert Rev Vaccines 3 4 Suppl. 2004 S169 S177
28. Z. Hel, D. Venzon, M. Poudyal, W.P. Tsai, L. Giuliani, and R. Woodward Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques Nat Med 6 10 2000 1140 1146
29. E. Tryniszewska, J. Nacsa, M.G. Lewis, P. Silvera, D. Montefiori, and D. Venzon Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy J Immunol 169 9 2002 5347 5357
30. E. Tryniszewska, J. Nacsa, M.G. Lewis, P. Silvera, D. Montefiori, and D. Venzon Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy J Immunol 169 9 2002 5347 5357
31. S.K. Kundu, D. Katzenstein, L.E. Moses, and T.C. Merigan Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine Proc Natl Acad Sci USA 89 23 1992 11204 11208
32. E. Sandstrom, and B. Wahren Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group Lancet 353 9166 1999 1735 1742
33. B. Hejdeman, A.C. Bostrom, R. Matsuda, S. Calarota, R. Lenkei, and E.L. Fredriksson DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy AIDS Res Hum Retroviruses 20 8 2004 860 870
34. G.K. Robbins, M.M. Addo, H. Troung, A. Rathod, K. Habeeb, and B. Davis Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization AIDS 17 8 2003 1121 1126
35. S.A. Plotkin, M. Cadoz, B. Meignier, C. Meric, O. Leroy, and J.L. Excler The safety and use of canarypox vectored vaccines Dev Biol Stand 84 1995 165 170
36. R.B. Belshe, G.J. Gorse, M.J. Mulligan, T.G. Evans, M.C. Keefer, J.L. Excler NIAID AIDS Vaccine Evaluation Group Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers AIDS 12 18 1998 2407 2415
37. T.G. Evans, M.C. Keefer, K.J. Weinhold, M. Wolff, D. Montefiori, and G.J. Gorse A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers J Infect Dis 180 2 1999 290 298
38. B. Fleury, G. Janvier, G. Pialoux, F. Buseyne, M.N. Robertson, and J. Tartaglia Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160 J Infect Dis 174 4 1996 734 738
39. H. Cao, P. Kaleebu, D. Hom, J. Flores, D. Agrawal, and N. Jones Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study J Infect Dis 187 6 2003 887 895
40. X. Jin, M. Ramanathan Jr., S. Barsoum, G.R. Deschenes, L. Ba, and J. Binley Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy J Virol 76 5 2002 2206 2216
41. T.R. Fleming One sample multiple testing for phase II clinical trials Biometrics 38 1982 143 151
42. Le Garff M, Gourlain K, Tubiana R, Haas P, Rabian C, Decoville T, et al. Cross recognition of HIV-specific CD8 responses in chronically HIV-1 infected patient immunized by an HIV-LAI recombinant Canarypox vector (vCP1433). In: Proceedings of the 10th conference in retroviruses and opportunistic infections, 2003.
43. A. Harari, S. Petitpierre, F. Vallelian, and G. Pantaleo Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy Blood 103 3 2004 966 972
44. S.A. Younes, B. Yassine-Diab, A.R. Dumont, M.R. Boulassel, Z. Grossman, and J.P. Routy HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity J Exp Med 198 12 1909-22
45. Levy Y, Gahery-Segard H, Durier C, Lascaux A-S, Meiffrédy V, Goujard C, et al. Immunological and virological efficacy of ALVAC-VIH 1433 and HIV Lipopeptides (Lipo-6T) combined with SC IL-2 in chronically HIV-infected catients - results of the ANRS 093 randomized study. In: Proceedings of the 10th conference in retroviruses and opportunistic infections, 2003.
46. F. Garcia, M. Plana, G. Mestre, M. Arnedo, C. Gil, and J.M. Miro Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection AIDS 16 13 2002 1761 1765